Introduction

Liver transplantation has become one of the mainstay treatments for selected patients with liver tumors. Based on the conclusions of the Consensus Conference held in Zurich in 2010, the last practice guideline on this topic was published in Lancet Oncology in 2012. Given the substantial changes in the management of liver tumors, as well as the advancements that have been made in the field of Transplant Oncology since 2010, there is a need to:

1. Update the concepts discussed in the previous Consensus Conference.
2. Identify unmet needs that will push the scientific community to improve the outcomes of patients with liver cancers.

The Consensus Conference will be a shared effort between the International Liver Cancer Association and the International Liver Transplantation Society, both leading the management and guidelines in Transplant Oncology for primary liver cancer.

The appointed Working Groups comprised of experts in the field of liver transplantation will address the following main topics:

- How to select patients with HCC and iCCA for liver transplantation to optimize the outcomes.
- How to manage patients in the waiting list and which are the best neoadjuvant treatments.
- How to incorporate new therapies for both HCC and iCCA for patients undergoing liver transplantation.
- How to best manage post-transplant cancer recurrences after liver transplantation.

This will be a very exciting and multidisciplinary conference involving, among many other specialties, medical and radiation oncologists, surgeons, hepatologists, radiologists.
LEARNING OBJECTIVES

1. Understand how to select patients for liver transplantation with HCC and iCCA.
2. Determine how to manage patients with HCC and iCCA before liver transplantation.
3. Determine how to incorporate new systemic and locoregional therapies for patients awaiting liver transplantation for HCC and iCCA.
4. Understand the differences between DDLT and LDLT for patients with HCC and iCCA.

TARGET AUDIENCE

- Hepatologists
- Medical Oncologists
- Radiation Oncologists
- Radiologist
- Transplant Surgeons
- Surgical Oncologists
- Pathologists
- Patient advocates
- Interventional Radiologists
- Nurses

WORKING GROUPS

1. Assessment of Candidates with HCC for Liver Transplantation
2. Criteria for Listing Patients with HCC
3. Immunotherapy and LT
4. LDLT vs. DDLT
5. Post-transplant Management
6. The Role of LT for Intrahepatic Cholangiocarcinoma
7. The Patient’s Perspective on Liver Transplantation for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
2024 ILTS-ILCA CONSENSUS CONFERENCE
Liver Transplantation for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

ILTS Executive Committee 2023-2024

President
Mark Ghobrial
Methodist Hospital
Houston, USA

President-Elect
Nazia Selzner
University of Toronto
Toronto, Canada

Treasurer
Bijan Eghtesad
Cleveland Clinic
Cleveland, USA

Secretary
Valeria R. Mas
University of Maryland School of Medicine
Baltimore, USA

Past-President
Mohamed Rela
Dr. Rela Institute and Medical Center Chennai
Chennai, India

Consensus Conference 2024 Chairs

Gonzalo Sapisochin
University Health Network
University of Toronto
Toronto, Canada

Laura Kulik
Northwestern University
Chicago, USA

Mohamed Rela
Dr. Rela Institute and Medical Center Chennai
Chennai, India

Sudha Kodali
Methodist Hospital
Houston, USA

ILCA Executive Committee 2023-2024

President
Tim Meyer
University College London
London, United Kingdom

Past President
Jessica Zucman-Rossi
University Paris Descartes
Paris, France

Executive Secretary
Amit Singal
UT Southwestern Medical Center
Dallas, USA

Treasurer
Lorenza Rimassa
Humanitas University, Humanitas Cancer Center
IRCCS Humanitas Research Hospital
Milan, Italy

Head of External Relations
Stephen Chan
Clinical Oncology - The Chinese University
Hong Kong

Consensus Conference 2024 Local Chair

Marina Berenguer
La Fe University Hospital
Valencia, Spain
Thursday, February 1, 2024

08:00 – 08:30  Welcome from ILTS & ILCA
R. Mark Ghobrial, MD, PhD, FACS, FRCS. Houston Methodist Hospital, Houston, USA
Tim Meyer, MD, PhD, FRCP. University College London, London, United Kingdom

08:10 – 08:25  Introductory Remarks
Mohamed Rela, MS, FRCS, DSc, Dr Rela Institute and Medical Centre, Chennai, India
Gonzalo Sapisochin, MD, PhD, MSc. University of Toronto, Toronto, ON, Canada

08:25 – 08:45  Special Lecture
Liver transplantation for HCC - what the future holds?
Vincenzo Mazzaferro, MD, PhD. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Moderators: Gonzalo Sapisochin, MD, PhD, MSc - Laura Kulik, MD, PhD

Presentations of Working Groups’ Recommendations

08:45 – 10:00  Working Group A - Assessment of candidates with HCC for liver transplantation
Working Group Leaders:
David Victor, MD, PhD. Houston Methodist Hospital, Houston, USA
Monica Lewinska, MD, PhD. University of Copenhagen, Copenhagen, Denmark

Working Group Members:
Amit Singal, MD, PhD. UT Southwestern Medical Center, Dallas, USA
Jeong Min Lee, MD, PhD. Seoul National University Hospital, Seoul, South Korea
Wojciech Polak, MD, PhD. Erasmus MC, Rotterdam, Netherlands
Karim J Halazun, MD, PhD, FACS. Weill Cornell Medical College, New York, USA
Jordi Bruix, MD, PhD. University of Barcelona, Barcelona, Spain
Neehar Parikh, MD, MS. University of Michigan, Detroit, USA
Eric Vibert, MD, PhD. Hôpital Paul-Brousse – Hôpitaux universitaires Paris-Sud. Paris, France
Korosh Khalili, MD, PhD, FRCP. University of Toronto, Toronto, Canada

1. What is the optimal screening for patients with cirrhosis on the transplant list? Utility and role of tumor markers.
2. Is dynamic CT and or MRI enough to accurately diagnose the size and number of tumors?
3. What’s the role, if any, of additional modalities like PET and CEUS? Are any of these modalities able to predict aggressiveness?
4. Should there be an age limit in well compensated patients with cirrhosis and HCC for considering LT?
5. Is 5-year survival benefit the ‘tool’ to decide which patients to transplant?
6. When is it too early to offer transplant in the context of DDLT and LDLT?
7. Role of tumor biopsy in era of NGS. What is the role of circulating DNA in this setting?
8. NAFLD and Non-cirrhotic HBV with HCC. Criteria for resection vs. transplant? Salvage transplant – ab initio or at recurrence?
Liver Transplantation for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

10:00 – 10:30 Coffee Break

10:30 – 11:45 Working Group B - Criteria for listing patients with HCC

Working Group Leaders:
- Carmen Vinaixa, MD, PhD, Hospital Universitario La Fe, Valencia, Spain
- Nicole Rich, MD, UT Southwestern Medical Center, USA

Working Group Members:
- Vincenzo Mazzaferrro, MD, PhD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- Vatche Agopian, MD, PhD, Dumont - UCLA Liver Cancer Center, Los Angeles, USA
- Augusto Villanueva, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, USA
- Marina Berenguer, MD, PhD, Hospital Universitario La Fe, Valencia, Spain
- Robert J. Lewandowski, MD, FSIR, PhD, Northwestern University, USA
- Neil Mehta, MD, PhD, University Of California San Francisco Medical Center, San Francisco, USA
- Tanios Bekaii-Saab, MD, PhD, Mayo Clinic, Phoenix, USA

1. Should liver transplantation be restricted to HCC patients who have a predicted 5-year survival comparable to non-HCC patients? Should the OS be HCC specific (METROTICKET 2.0)?
2. Should size and number still be the main consideration for selecting patients for LT for HCC? Should AFP, AFP L3, and DCP be criteria for listing/maintaining on WL?
3. When is bridging needed and when it is not? What are the most adequate bridging therapies? What is the frequency of imaging while waiting, and what are the drop-out criteria?
4. Can expansion of criteria be done without downstaging?
5. Downstaging:
   - Best strategies?
   - Should there be an upper limit of DS or should all comers be included if appropriately DS?
   - What constitutes successful DS? MC, PR, mRECIST vs. RECIST,
   - What is the optimal time after DS to list for LT?
6. Should patients who received curative treatment (surgery, ablation) with no residual tumor but at high risk of recurrence be considered for transplantation?
7. Best biomarkers to monitor response – AFP, AFP-L3 + DCP, liquid biopsy, Radiomics, NLR, PLR
8. What are the best scoring systems to predict recurrence pre and post LT?
9. Should macrovascular invasion be considered as a Contraindication for LT? Degree of PVT, mandatory time after response prior to LT, optimal neoadjuvant treatment?
10. Surgical considerations of LT based on the receipt of specific LRT – SBRT.
11. If a patient cannot be granted an HCC MELD upgrade, what measures to be implemented to obtain an organ?

11:45 – 12:15 Special Lecture

Beyond size and number - how do we incorporate biomarkers in the field of LT for HCC?

Augusto Villanueva, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, USA

Moderators: Vatche Agopian, MD, PhD - Kymberly Watt, MD, PhD

www.ilca-online.org - www.ilts.org
12:15 – 12:45 Special Lecture
How do we incorporate molecular alterations and targeted therapies in the field of transplant for iCCA?
Grainne O’Kane, MD, PhD, St. James Hospital, Dublin, Ireland
Moderators: David Pinato, MD

12:45 – 13:45 Lunch Break

13:45 – 15:00 Working Group C - Immunotherapy and LT
Working Group Leaders:
David Pinato, MD, Imperial College London, London, United Kingdom
Marco Sanduzzi Zamparelli, MD, PhD, Hospital Clinic of Barcelona, Barcelona, Spain
Working Group Members:
Grainne O’Kane, MD, PhD, St. James Hospital, Dublin, Ireland
Parissa Tabrizian, MD, PhD, MSc, FASCO, Icahn School of Medicine at Mount Sinai, New York, USA
François Durand, MD, PhD, University Paris VII, Paris, France
Tim Meyer, MD, PhD, FRCP, University College London, London, United Kingdom
Prashant Bhangui, MS, MBBS, Institute of Liver Transplantation and Regenerative Medicine, Medanta, India
Valeria R. Mas, MSc, PhD, FAST, University of Maryland, Baltimore, USA
Josep M. Llovet, MD, PhD, Mount Sinai School of Medicine, USA
Sherrie Bhoori, MD, National Cancer Institute of Milan, Milan, Italy
Maen Abdelrahim, MD, PhD, PharmB, Weill Cornell Medical College Houston Methodist, Texas, USA

1. Who is a good candidate for IO pre–transplant?
   a. Should it be considered for bridging or downstaging to LT?
   b. Should patients with macrovascular invasion be considered for transplant after response to IO?
   c. Should there be a waiting period after response to ensure no recurrence of IO therapy?
   d. Is there an immunotherapy regimen that is less risky and does this differ according to class of agent?
   e. What should be the washout period for IO pre–transplant?
   f. Should post LT IS be different in those who received IO prior to LT to avoid rejection?

2. What is the safety and rationale to combine Loco–regional therapies, IO and TKIs in the waiting list?

15:00 – 16:15 Working Group D - LDLT vs. DDLT
Working Group Leaders:
Ashwin Rammohan, MD, MBBS, Dr Rela Institute and Medical Centre, Chennai, India
Madhukar S. Patel, MD, MBA, ScM, UT Southwestern, Dallas, USA
Working Group Members:
Deniz Balci, MD, PhD, Ankara University School of Medicine, Ankara, Turkey
Albert Chi-Yan Chan, MD, PhD, University of Hong Kong, Hong Kong, Hong Kong
Arvinder Singh Soin, MBBS, MS, FRCS, Medanta Institute, Gurugram, India
Taizo Hibi, MD, PhD, FACS, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan
James Pomposelli, MD, PhD, University of Colorado School of Medicine, Denver, USA
Dong Hwan Jung, MD, PhD, Asan Medical Center, Seoul, Korea
Ahmed Elsabbagh, MD, MS, MRCs, PhD, Mansoura University, Egypt
1. Should the indications for LDLT for liver tumors be different from those for DDLT?
   a. Outside Milan
   b. Downstaging
   c. Macrovascular invasion
   d. iCCA

2. If a patient is transplanted beyond DDLT criteria and LDLT grafts fails, is re-transplant an option? How? When?

3. Is LDLT inferior or superior to DDLT for HCC? Overall survival and recurrence rates. Should it be acceptable to be
   lower than for DDLT?

4. What are the risks and adverse events for live donors?

16:15 – 16:45 Coffee Break

16:45 – 18:00 Working Group E - Post-transplant Management

   Working Group Leaders:
   Eleonora De Martin, MD, PhD, Hospital Paul Brousse, Villejuif, France
   Ken Liu, MD, MBBS (Hons), BSc (Med), PhD, FRACP, Liver Centre Royal Prince Alfred Hospital, Sidney, Australia

   Working Group Members:
   Christian Toso, MD, PhD, Université de Genève, Geneva, Switzerland
   Stephen Chan, MD, PhD, Chinese University of Hong Kong, Hong Kong, Hong Kong
   Lorenzo Rimassa, MD, PhD, Humanitas University, Milan, Italy
   Bijan Eghtesad, MD, Cleveland Clinic, Cleveland, USA
   Pål-Dag Line, MD, PhD, FEBS, University of Oslo, Oslo, Norway
   Kymberly Watt, MD, PhD, Mayo Clinic, Rochester, USA

1. What should be the optimal follow-up and modality for cancer recurrence surveillance?
2. What is the optimal immunosuppression for patients transplanted for liver cancer? What is the timing to modify
   immunosuppression in this population (low FK levels)?
3. What is the management of post-transplant cancer recurrence?
4. What is the role of adjuvant systemic treatment, and the role of systemic treatment at the time of recurrence?
5. What is the role of ischemia-reperfusion injury in the risk of recurrence? What is the role of machine perfusion
   in this setting?
6. Is there a difference in recurrence depending on the etiology of liver disease or the type of donor?
7. Surgical resection for isolated post-LT recurrence.

18:00 – 19:15 Working Group F - The Role of LT for Intrahepatic Cholangiocarcinoma

   Working Group Leaders:
   Abdul Rahman Hakeem, MD, FRCS, PhD, SERF (USA), FEBS, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
   Antonio D’Allessio, MD, Imperial College London, London, United Kingdom
Liver Transplantation for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

Working Group Members:
Juan Valle, MB, ChB, MSc, FRCP, University of Manchester, United Kingdom
Milind Javle, MD, PhD, University of Texas, Houston, USA
Anjana Pillai, MD, PhD, University of Chicago, Chicago, USA
Alfred Kow Wei Chieh, MBBS, FRCS, FAMS, FACS, University of Singapore, Singapore, Singapore
Valérie Paradis, MD, PhD, Assistance Publique–Hôpitaux de Paris, Paris, France
Arndt Vogel, MD, PhD, Toronto General Hospital, Toronto, ON, Canada

1. What is the role of transplant in cirrhotic patients with iCCA?
2. What is the role of transplant in non-cirrhotic patients with iCCA?
   a. Is there any limitation of size and number?
   b. How should tumor biology be assessed?

19:15 – 19:30 Closing remarks
Marina Berenguer, MD, PhD, Hospital University La Fe, Valencia, Spain
Friday, February 2, 2024

08:30 – 09:00 Summary of Group recommendations
Sudha Kodali, MD, MBBS, Houston Methodist Hospital, Houston, USA

09:00 – 09:30 Special Lecture
How to design trials in liver transplantation for liver cancer?
Jordi Bruix, MD, PhD, University of Barcelona, Barcelona, Spain

Moderators: Amit Singal, MD, PhD - Nazia Selzner, MD, PhD

09:30 – 10:00 Special Lecture
Patient Journey
Melinda Bachini Cholangiocarcinoma Foundation

Moderator: R. Mark Ghobrial, MD, PhD, FACS, FRCS

10:00 – 10:30 Working Group G - The Patient’s Perspective on Liver Transplantation for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
1. Zorana Maravic, Digestive Cancers Europe
2. CCF statement - Stacie Lindsey, Cholangiocarcinoma Foundation

10:30 – 10:50 Coffee Break


13:20 – 13:30 Closing Remarks
Laura Kulik, MD, PhD, Northwestern Medicine Organ Transplantation Center, Chicago, USA
CME Accreditation

The ILTS-ILCA 2024 Consensus Conference on Liver Transplantation for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma, Valencia, Spain 01/02/2024 – 02/02/2024, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 11.5 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applictations.

“Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Information regarding the conversion of EACCME® credits:

Credit will be converted based on one (1) hour of participation equalling one credit for all activities. Physicians wishing to convert EACCME® credits to AMA PRA Category 1 Credit™ will be required to access the AMA website at https://edhub.ama-assn.org/pages/applictations to obtain the necessary paperwork and instructions. Physicians and other health care professionals will be required to pay a processing fee to the AMA.

For other countries, please contact the relevant national/regional accreditation authority.
2024 ILTS-ILCA CONSENSUS CONFERENCE
Liver Transplantation for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

ILTS Headquarters

K.I.T. Group GmbH
Association & Conference Management
Kurfürstendamm 71
10709 Berlin, Germany
Phone: +49 (0) 30 24603 349
Fax: +49 (0) 30 24603 200
E-mail: ilts@ilts.org

Conference Venue

ADEIT – Fundación Universidad –
Empresa de la Universitat de València
Plaza Virgen de la Paz. 3.
46001 Valencia, Spain
https://espacios.adeituv.es/en/

Registration

Please register here by January 29, 2024
23:59 CET (GMT+2)
Should you require further assistance please don’t hesitate
to contact the ILTS Registration Department:
E-Mail: registration-consensus@ilts.org
Hotline: +49 (0) 30 24603 410

Accommodation

at Conference Venue Hotel

Accommodation can be requested through the registration
form, more info available here:
https://ilts.org/events/2024-ilts-ilca-consensus-conference/
Our Supporters

Gold Sponsors

AstraZeneca

Roche

Boston Scientific

Advancing science for life™

Silver Plus Sponsors

FUJIFILM

Value from Innovation

paladin

TransMedics®